Archives

The Moli-sani study (www.moli-sani.org) is a cohort study aiming at evaluating the risk factors (environmental, genetics, bio-molecular) linked to chronic-degenerative disease with particular regard to cancer, cardiovascular, cerebrovascular and neurodegenerative disease.
The study has recruited, between March 2005 and April 2010, 24,325 people aged ³ 35 living in the Molise region, from city hall registries by a multistage sampling. Exclusion criteria were pregnancy at the time of recruitment, disturbances in understanding or willingness, current poly-traumas or coma, or refusal to sign the informed consent. Participation rate was 70%.
All subjects underwent electrocardiogram and spirometric tests aimed to evaluate pulmonary diffusion capacity, gas diffusion and pulmonary volumes through plethysmography.
The European Prospective Investigation into Cancer and Nutrition FFQ was used to determine daily nutritional intakes consumed in the past year.
A follow-up based on linkage with hospital discharge records (SDO) and mortality regional registry was performed at December 2011 with a median of 4.3 years and at December 2014 with a median of 9.6 years. Outcomes analysed at follow-up are: mortality for any and specific causes, hospitalization and hospital stay, coronary artery disease, stroke, atrial fibrillation, heart failure, diabetes, cancer.

The Parkinson’s Progression Marker Initiative (PPMI) is an observational, international study designed to establish biomarker defined cohorts and identify clinical, imaging, genetic and biospecimen Parkinson’s disease (PD) progression markers to accelerate disease modifying therapeutic trials. A total of 423 untreated PD, 196 Healthy Control (HC), 64 SWEDD (scans without evidence of dopaminergic deficit) subjects, and 65 Prodromal subjects (individuals with hyposmia or REM Sleep Behavior Disorder) were enrolled. PPMI is actively enrolling affected and unaffected individuals with genetic mutations in LRRK2, GBA, or SNCA through the end of 2018. For the most up to date enrollment numbers, please visit http://www.ppmi-info.org/study-design/study-cohorts/. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.

Current evidence on older adults is derived from population-based cohort studies and randomized controlled trials, which may not include frail individuals. Data are lacking on older outpatients, a potentially diverse population. To bridge the gap between current evidence and clinical practice needs, the Milan Geriatrics 75+ Cohort Study was designed as an observational hospital-based outpatient cohort study. This study included 1861 new consecutive outpatients aged ?75 years who attended a first comprehensive visit at the Geriatric Unit of ‘I.R.C.C.S. Ca’ Granda’ in Milan, Italy, in the period between January 3, 2000 and March 25, 2004. These participants routinely underwent an extensive standardized structured medical examination and comprehensive geriatric assessment with trained physicians. At baseline, data were collected on reason for referral, demographics, physiological anamnesis, past and present medical history and medication use. Moreover, medical examination and anthropometric measurements were performed. Cognitive function was assessed using the 30-item Mini-Mental State Examination (MMSE). Functional status was evaluated using Katz’ Activities of Daily Living (ADL) and Lawton’ Instrumental Activities of Daily Living (IADL) questionnaires. At 10-year follow-up, all-cause mortality was assessed by collecting data from the Register Office of Milan or other town of residence.

Last Update 21/09/2017

In this epidemiological study we examined the prevalence of medical comorbidity in elderly subjects with cognitive deficits and dementia. The ReGAl Project (Rete Geriatrica Alzheimer- Geriatric Network on Alzheimer’s disease) collected data in 33 Italian Geriatric memory clinics from January 2001 to December 2005. A total of 4,075 patient were recruited.

Last Update 21/09/2017

The EADC-PET project (EAPP, The European Alzheimer’s Disease Consortium PET project) is a spontaneous multicentric study (ProtocolDraftSep2008; ProtocolDraftFeb2009) involving at the moment five Centres in four Countries (CENTRES), belonging to the EADC consortium. It was launched during the EADC meeting in Amsterdam, during fall 2007, by Flavio Nobili (Genoa) who is the Principal Investigator.

The project aims at sharing FDG-PET, MRI, neuropsychological, genetic, EEG and clinical information of patients with amnestic Mild Cognitive Impairment (aMCI) and matched healthy controls. Information is uploaded in a safe FTP facility on the server of University of Genoa. Username and password have been provided to all participants. Use of data is regulated by a ‘Confidentiality Disclosure Agreement’ that can be downloaded from this web site (Confidential_Disclosure_Agreement). The Centres propose original studies by sending a formal proposal to all participants who can agree or disagree, or propose modifications/suggestions to the original proposal.

The objective is to follow-up aMCI patients with clinical and neuropsychological examinations to pick up conversion to Alzheimer’s dementia or to other forms of dementia. FDG-PET can be analyzed by means of several post-processing strategies to highlight glucose metabolic information and to identify the characteristics of what is today called ‘prodromal’ AD.

Last Update 21/09/2017

All people aged 65-84 listed in the population registers of the 12 Italian participating towns as resident and alive on the 31.12.2002. The community based random sample was stratified by gender and 5-year age classes following an equal allocation strategy.

The general objective of IPREA-FU is to improve the evidence base on the preclinical phase of dementia, providing a better insight into its heterogeneous evolution.

Last Update 21/09/2017

This is the largest multi-centre study of ageing in men in the world and intends to identify the nature and frequency of some of the symptoms of ageing in men, the relationships between these symptoms to hormonal changes and other risk factors.

In total, 3369 men in 8 different countries in Europe are taking part in the study. These 8 centres are Manchester – UK, Malmo – Sweden, Tartu – Estonia, Lodz – Poland, Szeged – Hungary, Florence – Italy, Santiago de Compostela – Spain, Leuven – Belgium. In each centre, ~400 men aged between 40 and 79 years at the start of the study have been recruited. They will be followed up to look for future changes in their hormonal and general health status. The men will be investigated initially on two occasions, at the start and then ~5 years later. It is highly likely that the study will continue beyond 5 years and further testing will be organised subsequently. The aims of the study are to:

  1. Document geographical variations in the ageing-related involution decline of endocrine function in European men;
  2. Explain the variability in the rate of secular decline in endocrine functions on the basis of socio-demographic, lifestyle, co-morbid, ethnic/racial, or genetic factors;
  3. Predict the physical and psychological health status of individuals based on the variation in ageing-related endocrine decline and changes in body composition.

Last update – 24/04/2017

The European Prospective Investigation into Cancer and Nutrition (EPIC) is a prospective cohort with more than 521,000 study participants enrolled from 23 centres in 10 western European countries. Detailed information on diet, lifestyle characteristics, anthropometric measurements, and medical history was collected at recruitment (1992-1999).

Biological samples including plasma, serum, leukocytes, and erythrocytes were also collected at baseline from 387,889 individuals and are stored at the International Agency for Research on Cancer – World Health Organization (IARC-WHO) and mirrored at EPIC collaborating centres. Overall, the EPIC biorepositories host more than 9 million aliquots, constituting one of the largest biobanks in the world for biochemical and genetic investigations on cancer and other chronic diseases. Follow-up measures of lifestyle exposures have been collected and will be centralized at IARC in 2016.

Last update – 25/04/2017

InveCe.Ab (Invecchiamento Cerebrale ad Abbiategrasso) is a longitudinal, population-based study of disorders of brain ageing involving the assessment and long-term monitoring of the physical conditions and cognitive status. The target population comprises all Abbiategrasso residents born between 1935 and 1939, a reference sample, according to Population Register data, of around 1,700 people.

Those who agreed to participate in the Invece.Ab study were enrolled in a cross-sectional assessment and will be contacted two and four years after the initial data collection to participate in the longitudinal survey. Both the cross-sectional and longitudinal assessments include a medical evaluation, a neuropsychological test battery, several anthropometric measurements, a social and lifestyle interview, blood analyses, and the storage of a blood sample for the evaluation of putative biological markers.

Last update – 02/05/2017

The key goal of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6. To this end, a newly developed and validated ataxia scale (Scale for the Assessment and Rating of Ataxia, SARA) will be used. EUROSCA-NHS has a number of secondary aims including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily living (ADL) and quality of life (QoL), and identification of predictors of disease progression and survival.

Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ﾱ 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

Last update – 12/08/2017